However, other analysts remain confident with the company's stock by retaining the "buy" or "outperform" rating, with a target price of $95. Twelve gave a "buy" rating, two with "overweight", and sixteen with "hold". In average, Amgen is rated "overweight" with a consensus price target of $94.52.
In addition, a quarterly dividend was recently declared at $0.47 per share scheduled at March 7th and an annualized dividend of $1.88. This is an increase from Amgen's previous quarterly dividend of $0.36. Amgen has $1.13 billion worth of stock held by ETFs, and has a yield of 2.17 percent.
 The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.nationaltradersassociation.org/r/entire_report/9516_ARNA ][ 2 ] The Free Research Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.nationaltradersassociation.org/r/entire_report/7b3e_AMGN ] Consider National Traders Association Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop -- long before they become the next top news on major financial networks. Contact: Demi Lapierre Email: press@NationalTradersAssociation.org Main: +1-(702)-212-4493 SOURCE National Traders Association